Can be considered in patients with high risk for surgery and anesthesia (e.g., major health conditions) or desire to avoid surgery.
Observation Protocol
- Yearly calcium and PTH levels (blood test), kidney function labs (blood test), periodic DEXA (bone density) imaging.
Medical therapies – goal to prevent effects of pHPT, does not cure the underlying cause.
- Sensipar (Cincalcalcet).
- Can decrease calcium and PTH levels.
- No effect on bone mineral density (prevention or reversal of bone thinning).
- Bisphosphonates (e.g., Fosamax).
- Can increase bone mineral density.
- No effect on calcium and PTH levels.
- No single medical treatment is successful in reducing both blood calcium levels and stabilizing bone thinning.
- Lifelong treatment is necessary.
- These medications are associated with their own risk of side effects and must be monitored closely.
- Often more expensive than definitive treatment with surgery.
“Observation and medical therapy are less effective and less cost-effective, even when the patient is considered asymptomatic,” when compared to surgery. – American Association of Endocrine Surgeons Guidelines for Definitive Management of Primary hyperparathyroidism.